Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70179 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2025. Written by Ankit Kumar Singh and 8 co-authors. Institution: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India. Major MEDLINE topics: Proto-Oncogene Proteins B-raf, Sulfonamides, Antineoplastic Agents, Drug Design. 28 references. Funded by: Science and Engineering Research Board, Indian Council of Medical Research, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (original language)
BRAF is one of the most commonly mutated oncogenes in human cancers. More than 90% of BRAF mutations are associated with malignant melanoma. Given the pivotal role of BRAF V600E/WT mutations in melanoma progression and therapy resistance, our study focused on the design of phenyl‐substituted pyrimidin‐benzenesulfonamide hybrids in the [αC‐OUT/DFG‐IN] conformation, inspired by previously synthesized molecules structurally related to FDA‐approved BRAF inhibitors. A total of ten derivatives were synthesized, and their ADME‐T properties, in silico binding affinities, in vitro cytotoxic activities against a melanoma cell line and BRAF V600E/WT kinase assay were thoroughly evaluated. All compounds exhibit selective and stronger affinity for the BRAF V600E mutant over the wild‐type BRAF protein and also adhere to Lipinski's Rule of Five. Overall, both computational and biological evaluations support that the synthesized compounds, particularly VA03 , exhibit greater potency and selectivity toward the BRAF V600E mutant protein. Furthermore, the presence of electron‐withdrawing groups at the R 1 position appears to significantly enhance the cytotoxic activity of these derivatives.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India.
- Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, Uttar Pradesh, India.
- Department of Pharmaceutical Analysis, Quality Assurance and Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to Be University), Hyderabad, Telangana, India.
- Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
ORCID profiles: Amita Verma
Funding
- Science and Engineering Research Board
- Indian Council of Medical Research
- Department of Science and Technology, Ministry of Science and Technology, India
Cite
APA
Singh, A. K., Prajapati, V., Sah, V. K., Kumar, A., Kalsi, A. S., Pathak, P., Khalilullah, H., Verma, A., & Kumar, P. (2025). Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70179
Vancouver
Singh AK, Prajapati V, Sah VK, Kumar A, Kalsi AS, Pathak P, et al. Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70179
BibTeX
@article{Singh2025,
author = {Singh, Ankit Kumar and Prajapati, Vineet and Sah, Vimlendu Kumar and Kumar, Adarsh and Kalsi, Amandeep Singh and Pathak, Prateek and Khalilullah, Habibullah and Verma, Amita and Kumar, Pradeep},
title = {Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70179}
}
EUVIMED